Search PubMed⌕ Search

Biomedical subjects

S Stella

Publications and source records attributed to S Stella.

83 records · Page 5Linked to original sources
PubMedDate not supplied

[Octreotide in surgery].

Explore the source record for details and available documents.

Endocrine Gland Neoplasms↗
PubMedDate not supplied

[Indications and surgical treatment of Crohn disease].

On the basis of their experience (a series of 21 surgical approaches), the authors subdivide the indications for surgical treatment into absolutes and relatives. They recommend to operate also for relative indications in order to improve the patient's way of life, avoiding the establishment of extensive adhesions, under-nourishment and invalid subocclusive symptomatology. As the surgical treatment is not curative and is burdened from repeated operations, the authors suggest using a conservative surgery. They confirm the uninfluence, to prevent fistula and/or local recurrence, to carry out an anastomosis on healthy or slightly macroscopic disease tissues.

Crohn Disease↗
PubMedDate not supplied

Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutralized in vivo by GM-CSF administration.

BACKGROUND: GM-CSF has broad clinical applicability as a potent myelopoietic stimulator. However, its function is not restricted to the myelopoietic system and several observations suggest that GM-CSF may interfere with the hemostatic balance. In order to assess whether GM-CSF has any influence on hemostasis, we evaluated some coagulative and fibrinolytic parameters in patients treated with GM-CSF following chemotherapy. METHODS: Fibrinolytic activity (FA), fibrinogen and D-dimer were evaluated before and after high-dose cyclophosphamide in 6 patients additionally treated with GM-CSF and in 5 control patients; moreover, tissue plasminogen activator (tPA) was assayed in those treated with GM-CSF. Comparative in vitro analysis was performed on cultured endothelial cells before and after exposure to GM-CSF. RESULTS: Control patients showed a significant decrease in plasma FA after chemotherapy compared to basal values (FA/mm2: 15.6 +/- 2.1 at day + 2 and 20.8 +/- 19 at day + 4 vs. 103.8 +/- 64.2 at day 0; p < 0.005); conversely, no FA reduction was observed in GM-CSF-treated subjects. In this latter group a marked increase in tPA antigen was seen, consistent with enhanced FA. No significant changes in plasma D-dimer and fibrinogen values were detected in the two groups. tPA, urokinase-type plasminogen activator, PAI-1 and procoagulant activity were evaluated in vitro on cultured human endothelial cells and found to be unchanged following GM-CSF addition. CONCLUSIONS: The results demonstrate that high-dose chemotherapy may negatively influence plasma FA. This adverse side effect is neutralized by GM-CSF administration. The discrepancy found between in vitro and in vivo GM-CSF activity on hemostatic may be explained by in vivo GM-CSF stimulation of cell types other than endothelial cells.

Adult↗
PubMedDate not supplied

[Phyllodes breast tumors: apropos 2 cases].

The observation of two cases of phyllode tumors of the breast, one benign and the other malignant, brought the Authors to focus the fundamental aspects of these neoplasias. The histologic coexistence of both epithelial and connectival components, a relative unpredictable clinical evolution, the high frequency of recurrences, the stromal hyperproduction and modifications as expression of malignancy, and the need for large excisions are the fundamental characteristics of these tumors, which are considered transitional forms between benignity and malignancy.

Breast Neoplasms↗